Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 15 ... vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
Keywords: , Other Consumer, Health, ... Listeria monocytogenes (Lm) bacterium to simultaneously secrete two different antigen-adjuvant fusion proteins.
Under a patent-pending filed on May 26, 2009 with the US ...
2009 OCT 5 ... vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. Keywords: , Seniors, Women, Other Consumer, ... patent expands the Company's intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A. Advaxis' platform technology ...
2009 JUL 6 ... < .001). These responses were validated by using three separate techniques to measure immunological activity and showed that Oncophage evoked tumor-specific T cells and natural killer ... later this year. About Oncophage In April 2008, Oncophage was approved in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence. ...
2009 JUN 15 ... treatment in transplanted patients was feasible and did not seem to induce severe immunological effects. Adjuvant therapies to reduce cytopenias are frequently required, principally ...
2009 NOV 23 ... published their study in Clinical and Vaccine Immunology (Adjuvants Induce Distinct Immunological Phenotypes in a Bovine Tuberculosis Vaccine Model. Clinical and Vaccine Immunology, ... antigen Rv3019c, we have evaluated the induction of relevant immune responses by adjuvant formulations directly in the target species for bovine TB vaccines and compared these to ...
2009 OCT 5 ... golden needle mushroom Flammulina velutipes and has previously been reported to trigger immunological responses in both mouse and human lymphocytes. In this study, we evaluated the potential ... human lymphocytes. In this study, we evaluated the potential application of Fve as an adjuvant for tumor immunotherapy and examined the underlying mechanism(s)." "When ...
2009 JUN 15 ... hydrophilic moiety smaller space, respectively, which may lead to the acceleration of immunological studies on this product."
Uenishi and colleagues published their study ... comparatively. The CWS of Mycobacterium bovis BCG has long been expected as a potent adjuvant for immunotherapy of malignant tumor," scientists in Osaka, Japan report.
...
2009 SEP 28 ... an HSV-2 (herpes) vaccine and a universal influenza vaccine. "The robust immunological responses seen with Juvaris' adjuvant, JVRS-100, create a significant breakthrough ...
2009 JUN 29 ... self proteins. This allows us to use aluminium hydroxide, the agent first approved as immunological adjuvant for human use and, thus, exhibiting an excellent safety profile. Second, AFFITOPES ...
2009 AUG 31 ... cytokines. CpG-ODNs have promising anti-neoplastic potential. They exert a pronounced immunological response both in the native murine urinary bladder and in murine TCC," wrote P.J. ... and adjuvants for a strong Th1-response and there is evidence for a direct and/or adjuvant anti-neoplastic effect. The purpose of this study was to examine the local effects of ...
2009 OCT 5 ... writing in the journal Cancer Science report. "Here we tested the immunological importance of lymph nodes in treatment of ovarian cancer patients with BCG-CWS. After ... of Mycobacterium bovis Bacillus Calmette-Guerin (BCG-CWS) has been used as an effective adjuvant for immunotherapy of a variety of cancer patients," scientists writing in the journal ...
2009 JUN 22 ... Scientists discuss in 'Molecular and immunological characterization of Babesia gibsoni and Babesia microti heat shock protein-70' new ... "Taken together, these results emphasize the potential of HSP-70s as a molecular adjuvant vaccine."
Terkawi and colleagues published their study in Parasite ...
2009 JUL 20 ... of mannose in nanoceramic formulation may additionally lead to increased stability and immunological reactions. Immunization with MSP-1(19) in nanoceramic-based adjuvant systems induced a ...
2009 OCT 5 ... adjuvant activity, driving strong cellular and humoral immunity that may be an effective immunological adjuvant in DNA vaccination against HIV-1." Muthumani and colleagues published ...
2009 SEP 21 ... Immunopharmacology and Immunotoxicology (Ipomoea obscura (L.) enhances the functions of immunological effector cells, inhibits proinflammatory cytokines and nitric oxide production by LPS ... of side effects. Botanical based immunomodulators are often employed as supportive or adjuvant therapy to overcome the undesired effects of cytotoxic chemotherapeutic agents and to ...
2009 OCT 12 ... and colleagues published their study in the Journal of Clinical Oncology (Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 ... with 200 mu g granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant, six times at 14-day intervals. All patients were observed for 1 year after treatment. ...
2009 AUG 3 ... vaccines. ." Zhu and colleagues published their study in the Journal of Immunological Methods (Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA). Journal of ... study from the United States, "Alhydrogel ® (aluminum hydroxide) is a widely used adjuvant in the US. Regulatory authorities require that vaccines be tested to determine the ...
2009 NOV 9 ... cancer patients," scientists in Osaka, Japan report. "Here we tested the immunological importance of lymph nodes in treatment of ovarian cancer patients with BCG-CWS. After ... of Mycobacterium bovis Bacillus Calmette-Guerin (BCG-CWS) has been used as an effective adjuvant for immunotherapy of a variety of cancer patients," scientists in Osaka, Japan report. ...
2009 SEP 7 ... have been published. "Poly(lactide-co-glycolide) (PLGA) microparticles (MP) possess immunological adjuvant properties. Yet, exploitation of their full potential has just begun," investigators in ...
2009 AUG 4 ... The mean patient age was 6.75 years (median, 4.79). The most common reasons for CAM were immunological and allergy problems (30%), infectious diseases (21.4%), and attention deficit and ... Ben-Gurion University. The researchers concluded: "CAM can be an adjuvant therapy for children with common chronic pediatric problems." Erez and ...
